Search
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalBrian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy". … Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidideLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. … [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.
Categories: Drugs Used in Hereditary AngioedemaProducts: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADETValganciclovir
go.drugbank.com/drugs/DB01610ApprovedInvestigationalValganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. … As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Categories: Heterocyclic Compounds, 2-RingProducts: AVALCEPT 50 MG / ML ORAL ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 100 ML, RUNAVIR®450 MGBarium sulfate
go.drugbank.com/drugs/DB11150ApprovedIt is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield [L1957]. This drug is used as a contrast agent in diagnostic x-ray procedures. … Barium sulfate is an inorganic compound with the chemical formula BaSO4 [L1957]. Barium sulfate occurs in nature as the mineral _barite_.
Mixtures: E-Z HD SULFATODE BARIO PARA SUSPENSION, E-Z HD SULFATODE BARIO PARA SUSPENSIONCategories: Compounds used in a research, industrial, or household setting, X-Ray Contrast ActivityCiclopirox
go.drugbank.com/drugs/DB01188ApprovedInvestigationalCiclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. … In particular, the agent is especially effective in treating Tinea versicolor.
Mixtures: Ciclopirox 3% / Itraconazole 5% / Urea 20%, Ciclopirox 8% / Fluconazole 1% / Terbinafine HCl 1%Categories: Heterocyclic Compounds, 1-RingBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … Briviact received FDA approval on February 19, 2016 [L760].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: BRIVIACT ® 50 MG COMPRIMIDOS RECUBIERTOS., BRIVIACT 50 MG FILM KAPLI TABLET ,56 FILM KAPLI TABLETRisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigationalRisankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). … [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Products: Skyrizi 75 mg solution for injection in pre-filled syringe, Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 ADETPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers. … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: KEYTRUDA® 100 MG, KEYTRUDA 100 MG/4 ML IV INFUZYONLUK COZELTI İÇEREN FLAKON, 1 ADETArgatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalArgatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. … Argatroban is a direct, selective thrombin inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: Argatra 1 mg/ml Infusionslösung, Argatroban Accord 1 mg/ml InfusionslösungElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalIt is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerSynonyms: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB, IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULIN